1. Home
  2. DH vs FHTX Comparison

DH vs FHTX Comparison

Compare DH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$1.22

Market Cap

283.1M

Sector

Technology

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.66

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
FHTX
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
360.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DH
FHTX
Price
$1.22
$5.66
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$3.43
$11.71
AVG Volume (30 Days)
364.0K
115.3K
Earning Date
05-25-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.28
32.48
EPS
N/A
N/A
Revenue
$241,521,000.00
$22,602,000.00
Revenue This Year
N/A
$40.91
Revenue Next Year
$1.21
$11.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$2.94
52 Week High
$4.70
$6.95

Technical Indicators

Market Signals
Indicator
DH
FHTX
Relative Strength Index (RSI) 22.47 50.64
Support Level N/A $4.44
Resistance Level $2.96 $5.85
Average True Range (ATR) 0.12 0.35
MACD -0.02 -0.01
Stochastic Oscillator 21.64 63.86

Price Performance

Historical Comparison
DH
FHTX

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: